Basic Study
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Mar 15, 2023; 15(3): 504-522
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.504
Figure 7
Figure 7 Mu Ji Fang Granules alleviated the modulation of Transforming growth factor β1 inhibitor (LY364947) on the Transforming growth factor β1/ Mothers against decapentaplegic homolog signaling pathway, immune and apoptotic cytokines in HepG2 cells. A: Relative expression of Transforming growth factor β1(TGF-β1), Mothers against decapentaplegic homolog (SMAD) 2, p-SMAD2, SMAD4, and SMAD7 protein following treatment of HepG2 cells with TGF-β1 inhibitor (LY364947); B: Relative expression of Tumor necrosis factor α and Interferon gamma mRNA following treatment of HepG2 cells with TGF-β1 inhibitor (LY364947); C: Relative expression of Bax, and Bcl2 mRNA following treatment of HepG2 cells with TGF-β1 inhibitor (LY364947) (n = 4). Data are shown as mean ± standard deviation. aP < 0.01 vs Control [Mu Ji Fang Granules (MJF) 0 mg/mL]. bP < 0.05 vs Control [Mu Ji Fang Granules (MJF) 0 mg/mL]. cP < 0.01 vs Mu Ji Fang Granules 10 mg/mL. dP < 0.05 vs Mu Ji Fang Granules 10 mg/mL.